Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo ...

From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...

NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo ...

Find insight on Sanofi, ResMed, Lonza and more in the latest Market Talks covering the health care sector.

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

The White House on Friday said Novo Nordisk's weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a round of price negotiations with Medicare. The companies do not have to ...

As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval ...

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

Following a rough fourth quarter, we see the healthcare sector overall as undervalued, with a median discount to our fair ...